November 20, 2019
Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb
echo $thePR[ 'category' ]; ?>
November 15, 2019
Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma
echo $thePR[ 'category' ]; ?>
November 8, 2019
FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
echo $thePR[ 'category' ]; ?>
November 6, 2019
Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting
echo $thePR[ 'category' ]; ?>
October 31, 2019
Celgene Reports Third Quarter 2019 Operating and Financial Results
echo $thePR[ 'category' ]; ?>
September 20, 2019
Celgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients
echo $thePR[ 'category' ]; ?>
September 12, 2019
Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
echo $thePR[ 'category' ]; ?>
August 16, 2019
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
echo $thePR[ 'category' ]; ?>
July 30, 2019
Celgene Reports Second Quarter 2019 Operating and Financial Results
echo $thePR[ 'category' ]; ?>